阿斯利康(AZN.US)PD-L1+CTLA-4组合在华申报上市一线治疗NSCLC

智通财经2025-02-21

智通财经APP获悉，2月21日，CDE网站显示，阿斯利康(AZN.US)的PD-L1单抗度伐利尤单抗在华申报新适应症。根据阿斯利康2024年财报，此次申报的适应症为联合替西木单抗和标准治疗一线治疗无致敏表皮生长因子受体(EGFR)突变或间变性淋巴瘤激酶(ALK)基因组肿瘤畸变的转移性非小细胞肺癌(NSCLC)成年患者。此次上市申请是基于III期POSEIDON研究的积极结果。该研究在1013例...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2513606242?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-02-21 21:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2513606242","market":"hk","top_or_hot":-1,"title":"阿斯利康(AZN.US)PD-L1+CTLA-4组合在华申报上市 一线治疗NSCLC","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，2月21日，CDE网站显示，阿斯利康(AZN.US)的PD-L1单抗度伐利尤单抗在华申报新适应症。根据阿斯利康2024年财报，此次申报的适应症为联合替西木单抗和标准治疗一线治疗无致敏表皮生长因子受体(EGFR)突变或间变性淋巴瘤激酶(ALK)基因组肿瘤畸变的转移性非小细胞肺癌(NSCLC)成年患者。此次上市申请是基于III期POSEIDON研究的积极结果。该研究在1013例...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1253018.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>阿斯利康(AZN.US)PD-L1+CTLA-4组合在华申报上市 一线治疗NSCLC</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n阿斯利康(AZN.US)PD-L1+CTLA-4组合在华申报上市 一线治疗NSCLC\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-02-21 21:24 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1253018.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，2月21日，CDE网站显示，阿斯利康(AZN.US)的PD-L1单抗度伐利尤单抗在华申报新适应症。根据阿斯利康2024年财报，此次申报的适应症为联合替西木单抗和标准治疗一线治疗无致敏表皮生长因子受体(EGFR)突变或间变性淋巴瘤激酶(ALK)基因组肿瘤畸变的转移性非小细胞肺癌(NSCLC)成年患者。此次上市申请是基于III期POSEIDON研究的积极结果。该研究在1013例...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1253018.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1169590202.USD","symbol_name":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1253018.html","article_id":"2513606242","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2513606242","pubTimestamp":1740144275,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，2月21日，CDE网站显示，阿斯利康(AZN.US)的PD-L1单抗度伐利尤单抗在华申报新适应症。根据阿斯利康2024年财报，此次申报的适应症为联合替西木单抗和标准治疗一线治疗无致敏表皮生长因子受体(EGFR)突变或间变性淋巴瘤激酶(ALK)基因组肿瘤畸变的转移性非小细胞肺癌(NSCLC)成年患者。此次上市申请是基于III期POSEIDON研究的积极结果。该研究在1013例EGFR/ALK野生型转移性NSCLC患者中评估了度伐利尤单抗(1500mg)+替西木单抗(75mg)±标准治疗(铂类化疗)对比标准治疗的疗效和安全性。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","BK4007":"制药","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4568":"美国抗疫概念","PD":"PagerDuty, Inc.","BK4585":"ETF&股票定投概念","BK4588":"碎股","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","AZN":"阿斯利康","LU1829250122.USD":"高盛欧洲核心股票组合Acc","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4023":"应用软件","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC"},"translate_title":"AstraZeneca (AZN.US) PD-L1+CTLA-4 combination applies for marketing in China for the first-line treatment of NSCLC","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PD":1,"AZN":1},"content_text":"智通财经APP获悉，2月21日，CDE网站显示，阿斯利康(AZN.US)的PD-L1单抗度伐利尤单抗在华申报新适应症。根据阿斯利康2024年财报，此次申报的适应症为联合替西木单抗和标准治疗一线治疗无致敏表皮生长因子受体(EGFR)突变或间变性淋巴瘤激酶(ALK)基因组肿瘤畸变的转移性非小细胞肺癌(NSCLC)成年患者。此次上市申请是基于III期POSEIDON研究的积极结果。该研究在1013例EGFR/ALK野生型转移性NSCLC患者中评估了度伐利尤单抗(1500mg)+替西木单抗(75mg)±标准治疗(铂类化疗)对比标准治疗的疗效和安全性。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2513606242","isCrawlerRequest":true}

阿斯利康(AZN.US)PD-L1+CTLA-4组合在华申报上市 一线治疗NSCLC

精彩评论

阿斯利康(AZN.US)PD-L1+CTLA-4组合在华申报上市一线治疗NSCLC